Hepatitis A virus infections associated with clotting factor concentrate in the United States.
about
Sexually acquired hepatitis.Enteric hepatitis viruses.Efforts in minimizing risk of viral transmission through viral inactivation.Characterization of hepatitis A virus isolates from subgenotypes IA and IB in Rio de Janeiro, Brazil.Diagnosis of hepatitis a virus infection: a molecular approach.Nanofiltration of plasma-derived biopharmaceutical products.Treating haemophilia A with recombinant blood factors: a comparison.Haemophilia B: Christmas disease.Hepatitis A Virus and Hepatitis E Virus Seroprevalence Among Blood Donors in Tehran, IranCase report of a transfusion-associated hepatitis A infection.Phylogenetic analysis of a transfusion-transmitted hepatitis A outbreak.United Kingdom National Guideline on the Management of the viral hepatitides A, B and C 2015.Safety and efficacy of solvent/detergent-treated antihaemophilic factor with an added 80 degrees C terminal dry heat treatment in patients with haemophilia A.Hepatitis G virus in clotting factor concentrates.Viral safety of a pasteurized, monoclonal antibody-purified factor VIII concentrate in previously untreated haemophilia A patients.Inactivation of parvovirus B19 in coagulation factor concentrates by UVC radiation: assessment by an in vitro infectivity assay using CFU-E derived from peripheral blood CD34+ cells.Prevalence of nucleic acid sequences specific for human parvoviruses, hepatitis A and hepatitis E viruses in coagulation factor concentrates.Implementation of a hepatitis A prevention policy in haemophiliacs: results from the French cohort.Molecular and serologic tracing of a transfusion-transmitted hepatitis A virus.Multicenter evaluation of a commercial multiplex polymerase chain reaction test for screening plasma donations for parvovirus B19 DNA and hepatitis A virus RNA.Detection of hepatitis A virus from clotting factors implicated as a source of HAV infection among haemophilia patients in Korea.Occurrence of hepatitis A virus genotype III in Germany requires the adaptation of commercially available diagnostic test systems.A World Health Organization International Standard for hepatitis A virus RNA nucleic acid amplification technology assays.Causality assessment of suspected virus transmission by human plasma products.A new cluster of hepatitis A infection in hemophiliacs traced to a contaminated plasma pool.Persistent expression of canine factor IX in hemophilia B canines.Safety and efficacy of a sucrose-formulated recombinant factor VIII product for the treatment of previously treated patients with haemophilia A in China.Product choice and haemophilia treatment in the Netherlands.A model for a regional system of care to promote the health and well-being of people with rare chronic genetic disorders.Detection of hepatitis A viral RNA in sera of patients with acute hepatitis A
P2860
Q30843237-19805D23-24DE-47D2-8C4A-A0F2851E469BQ33596383-03FE6852-28E2-4239-87DF-D7696859A4B8Q34087433-ECAE5A37-F312-4147-91CF-6C8836EE2462Q34105513-3DD2D023-4815-458C-93AE-DEF63EFF6031Q34334021-D6A260F1-E8E3-4625-B282-8B97F92D3768Q35056870-B96D7D85-F8CD-4156-A7B1-3A2B6F54804FQ35779195-683D277E-EB14-4754-B4E3-C5AA89D2B553Q36221979-E97678A9-0CCF-4C71-9009-0432F3249113Q36805354-1F317882-479B-4C23-BCB0-00594ADC7878Q38201147-70E18165-D17F-43E7-81A9-9F8ECF7DED93Q40569042-2A7B471A-7D00-4B15-BF19-CC0924018EEEQ40990518-A96AF9B3-1578-465C-993E-117CE23C8E4FQ41733580-5AB53E81-BFC9-40A2-935F-2633E92C6C2AQ43042170-208FE875-228F-4A12-9504-96B085F9FCA7Q43548826-9EB90561-A7EE-4C24-9BD1-88370F3ACB25Q43584966-5F995FAE-13F9-4C42-B086-A62EE182AEF3Q44807693-4004DFD2-51DC-4B91-817A-31086DF8E06BQ45084513-0693FF7A-24E1-457D-BB7D-E38B4A6B5768Q45123607-D84321FE-DED2-4D40-B7EC-FB54AA525CD4Q45357632-6A7856CD-6144-4899-BF6F-7DCB9611EA1DQ45420875-70854C31-9783-4008-BF4C-82F4DA38BEB0Q45440825-D56E64BE-117D-46EE-AE04-D88D9E80462DQ45452599-79652541-8EE6-4170-9109-644FD4B309E2Q45736204-D6596E06-B82D-43B9-99A3-496F4A587DC5Q45855627-8F581BF3-E97B-4B76-A8AD-864814867EFBQ45862802-04A304C4-CFE8-4986-AD03-8002ADB95C8CQ45869276-36DECC63-4B25-4D4B-9D49-72C92C694F7DQ45873712-CB2A9BE4-B60D-499B-96B5-45CB0EC87F7CQ52993052-59F3405E-C338-4D36-9B47-C84B9D308440Q57728415-237A1413-869F-46DA-B24E-145C251FC808
P2860
Hepatitis A virus infections associated with clotting factor concentrate in the United States.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年学术文章
@wuu
1998年学术文章
@zh
1998年学术文章
@zh-cn
1998年学术文章
@zh-hans
1998年学术文章
@zh-my
1998年学术文章
@zh-sg
1998年學術文章
@yue
1998年學術文章
@zh-hant
name
Hepatitis A virus infections a ...... centrate in the United States.
@en
Hepatitis A virus infections a ...... centrate in the United States.
@nl
type
label
Hepatitis A virus infections a ...... centrate in the United States.
@en
Hepatitis A virus infections a ...... centrate in the United States.
@nl
prefLabel
Hepatitis A virus infections a ...... centrate in the United States.
@en
Hepatitis A virus infections a ...... centrate in the United States.
@nl
P2093
P1433
P1476
Hepatitis A virus infections a ...... centrate in the United States.
@en
P2093
McCaustland KA
Robertson BH
P304
P356
10.1046/J.1537-2995.1998.38698326337.X
P577
1998-06-01T00:00:00Z